These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35887946)

  • 1. Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study.
    D'Angelo S; Tirri E; Giardino AM; Mattucci-Cerinic M; Dagna L; Santo L; Ciccia F; Frediani B; Govoni M; Bobbio Pallavicini F; Grembiale RD; Delle Sedie A; Mulè R; Cantatore FP; Foti R; Gremese E; Conigliaro P; Salaffi F; Viapiana O; Cauli A; Giacomelli R; Arcarese L; Guggino G; Russo R; Puenpatom A; Capocotta D; Nacci F; Anelli MG; Picerno V; Binetti C; Iannone F
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
    Govoni M; Batalov A; Boumpas DT; D'Angelo S; De Keyser F; Flipo RM; Kellner H; Leroi H; Khalifa A
    Clin Exp Rheumatol; 2024 Mar; 42(3):642-650. PubMed ID: 37976120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
    Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
    Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study.
    Dejaco C; Mueller T; Zamani O; Kurtz U; Egger S; Resch-Passini J; Totzauer A; Yazdani-Biuki B; Schwingenschloegl T; Peichl P; Kraus A; Naerr GW
    Front Med (Lausanne); 2022; 9():881943. PubMed ID: 35721062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany.
    Krüger K; Burmester GR; Wassenberg S; Thomas MH
    Rheumatol Ther; 2020 Jun; 7(2):371-382. PubMed ID: 32303994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
    Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
    Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.
    Athanassiou P; Kotrotsios A; Kallitsakis I; Bounas A; Dimitroulas T; Garyfallos A; Tektonidou MG; Vosvotekas G; Livieratos A; Petrikkou E; Katsifis G
    Qual Life Res; 2022 May; 31(5):1385-1399. PubMed ID: 34839451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey.
    Akar S; Kalyoncu U; Dalkilic E; Emmungil H; Aziz A; Esen Y; Koc T
    Immunotherapy; 2021 Jul; 13(10):841-850. PubMed ID: 33955239
    [No Abstract]   [Full Text] [Related]  

  • 9. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
    Benavent D; Muñoz-Fernández S; De la Morena I; Fernández-Nebro A; Marín-Corral J; Castillo Rosa E; Taberna M; Sanabra C; Sastre C;
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231220818. PubMed ID: 38146537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry.
    Pombo-Suarez M; Sanchez-Piedra C; Garcia-Magallón B; Pérez-Gómez A; Manrique-Arija S; Martín-Doménech R; Colazo M; Campos C; Campos J; Del Pino-Montes J; Arteaga MJ; Cea-Calvo L; Díaz-González F; Gómez-Reino JJ
    Clin Rheumatol; 2021 Oct; 40(10):3979-3988. PubMed ID: 33907904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
    Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
    Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
    Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
    Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
    Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
    Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life golimumab persitence in patients with axial spondyloarthritis: post-hoc results of the prospective observational cohort study, GO-PRACTICE.
    Goupille P; Bertin P; Tubach F; Lespessailles E; Harid N; Sequeira S; Fayette JM; Fautrel B; Flipo RM
    Clin Exp Rheumatol; 2022 Jul; 40(7):1352-1360. PubMed ID: 34936548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
    Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Cea-Calvo L; Sánchez-Alonso F; Sánchez-Jareño M; Jovani V; García-Magallón B; Martínez-González O; Campos-Fernández C; Manero J; Díaz-Torne C; Bohórquez C; Ros-Vilamajó I; Pérez-Vera Y; Castrejón I
    Musculoskeletal Care; 2023 Mar; 21(1):189-197. PubMed ID: 35996810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.
    Jarlborg M; Courvoisier DS; Lamacchia C; Martinez Prat L; Mahler M; Bentow C; Finckh A; Gabay C; Nissen MJ;
    Arthritis Res Ther; 2020 May; 22(1):105. PubMed ID: 32375861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual Disease Burden in Patients With Axial Spondyloarthritis and Psoriatic Arthritis Despite Low Disease Activity States in a Multiethnic Asian Population.
    Liu V; Fong W; Kwan YH; Leung YY
    J Rheumatol; 2021 May; 48(5):677-684. PubMed ID: 33132217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.